

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:1091185 CAPLUS [Full-text](#)
 DN 147:378407

TI Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use

IN Putman, David G.; Hogenkamp, Derk J.; Dasse, Olivier A.; Whittemore, Edward R.; Jensen, Mark S.

PA Xytis Inc., USA

SO PCT Int. Appl., 52pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007109288	A2	20070927	WO 2007-US6958	20070320
	WO 2007109288	A3	20080403		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20080039453	A1	20080214	US 2007-726286	20070320
PRAI	US 2006-784514P	P	20060320		

AB Enantiomerically pure R-etifoxine and pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof are provided. Also provided are pharmaceutical compns. comprising the compds. and methods of treating disorders associated with central nervous system using the compds. and pharmaceutical compns. High performance liquid chromatog., performed using a CHIRALCEL OF column, was used to sep. racemic etifoxine. The absolute configuration of (+)-etifoxine was determined to be R by derivatization with the chiral adduct (S)-(+)-1-(1-naphthyl)ethyl isocyanate followed by x-ray crystallog. anal.


IT 23887-31-2, Clorazepate 29177-84-2, Ethyl Loflazepate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrug; enantiomerically pure R-etifoxine, pharmaceutical compns. thereof and methods of their use)


RN 23887-31-2 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
 7-chloro-2,3-dihydro-2-oxo-5-phenyl- (CA INDEX NAME)




RN 29177-84-2 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)




L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:1042227 CAPLUS [Full-text](#)
 DN 143:326401
 TI Process for preparing benzodiazepines
 IN Dowdell, Verity; Kelsey, Richard David; Carter, Malcolm; Henderson, Elisa
 Ann
 PA Arrow Therapeutics Limited, UK
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005090319	A1	20050929	WO 2005-GB1050	20050321
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20070293482	A1	20071220	US 2007-593665	20070802
PRAI	GB 2004-6280	A	20040319		
	GB 2004-6282	A	20040319		
	GB 2004-23462	A	20041021		
	WO 2005-GB1050	W	20050321		
OS	CASREACT 143:326401; MARPAT 143:326401				
GI					



I



II



III

AB A process for the preparation of benzodiazepines (R/S)-I [wherein R1 = alkyl or (hetero)aryl; R3 = halo, OH, alkyl; n = 0-3; X = -NH-, -N(alkyl)-, -CO-; R4 = H, CONH(alkyl); etc., or pharmaceutically acceptable salts thereof], which are active against respiratory syncytial virus (RSV), is disclosed. Some intermediates are claimed. As an example, acylation of 2-aminoacetophenone with bromoacetyl bromide (95%) followed by cyclocondensation with NH3 in refluxing methanol (95%) and subsequent N-protection with PMB-Cl (87%) gave benzodiazepine II (R = H). This compound underwent oximation with isoamyl nitrite in the presence of KOBu-t in toluene to afford oxime II (R = =NOH) (76%), which was reduced with H2-Ru/C to amine II (R = NH2) (81%). Crystallization induced dynamic resolution of the above racemate amine with (-)-Boc-Phe-OH (1 equivalent) and 3,5-dichlorosalicylaldehyde (0.04 equivalent) in toluene under stirring at rt provided (S)-II (R = NH2) (71% yield, 99.8%

e.e.). Following condensation with 2-fluorophenylisocyanate and deprotection with AlCl₃ in anisole led to urea III (91% for two steps).

IT 865475-34-9P

RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(asym. synthesis of 3-aminobenzodiazepines via oximation of benzodiazepines with isoamyl nitrite followed by Ru/C-catalyzed hydrogenation and crystallization induced dynamic resolution)

RN 865475-34-9 CAPLUS


CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, compd. with (3S)-3-amino-1,3-dihydro-1-[(4-methoxyphenyl)methyl]-5-phenyl-2H-1,4-benzodiazepin-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 865475-33-8

CMF C23 H21 N3 O2

Absolute stereochemistry.




CM 2

CRN 18942-49-9

CMF C14 H19 N O4

Absolute stereochemistry. Rotation (-).



IT 174698-37-4P 865475-36-1P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(asym. synthesis of 3-aminobenzodiazepines via oximation of benzodiazepines with isoamyl nitrite followed by Ru/C-catalyzed

hydrogenation and crystallization induced dynamic resolution)

RN 174698-37-4 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-1-[(4-methoxyphenyl)methyl]-5-phenyl- (CA INDEX NAME)



RN 865475-36-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-1-[(4-methoxyphenyl)methyl]-5-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 4173-63-1F, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 79890-53-8P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 103373-17-7P, 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 103373-21-3P,
3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 108895-98-3P,
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester 116842-74-1P, Pyrazine-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 119506-69-3P, 1-(3-Methoxyphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 156964-48-8P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 168162-29-6P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester 206115-23-3P,

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(m-
 tolyl)urea 368870-46-6P, Thiophene-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 368870-47-7P, Furan-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 368870-49-9P, Thiophene-2-carboxylic acid
 N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 368870-50-2P, Furan-2-carboxylic acid
 N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676127-95-0P, 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)urea 676127-96-1P,
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide
 676127-97-2P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)butyramide 676127-98-3P,
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isobutyramide
 676127-99-4P, 2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)propionamide 676128-00-0P,
 Cyclopentanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)amide 676128-01-1P,
 Cyclohexanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)amide 676128-02-2P,
 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)benzamide 676128-03-3P,
 4-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)benzamide 676128-04-4P,
 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)benzamide 676128-05-5P,
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-
 trifluoromethylbenzamide 676128-06-6P, Piperidine-1-carboxylic
 acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-07-7P, Morpholine-4-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-08-8P, 4-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)benzamide 676128-09-9P,
 3-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)benzamide 676128-10-2P, 4-Methylpiperazine-1-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-11-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)-2-trifluoromethylbenzamide
 676128-12-4P, 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)benzamide 676128-13-5P,
 2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)benzamide 676128-14-6P,
 2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)benzamide 676128-15-7P,
 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)benzamide 676128-16-8P,
 (S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-3-yl)benzamide 676128-17-9P,
 Benzo[b]thiophene-3-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-18-0P, 2,3-Dihydrobenzofuran-5-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-19-1P, Isoxazole-5-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-20-4P, Benzo[b]thiophene-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-21-5P, Thiophene-3-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 676128-22-6P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)isonicotinamide 676128-23-7P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide
676128-24-8P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)methanesulfonamide 676128-25-9P,
Propane-1-sulfonic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)amide 676128-26-6P, Butane-1-sulfonic
acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
676128-27-1P, 2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-28-2P,
3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzenesulfonamide 676128-29-3P,
4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzenesulfonamide 676128-30-6P,
2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzenesulfonamide 676128-31-7P,
3-(2-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one
676128-32-6P, 3-(3-Nitrobenzylamino)-5-phenyl-1,3-
dihydrobenzo[e][1,4]diazepin-2-one 676128-33-9P,
3-(4-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one
676128-34-0P, 3-(2-Methoxybenzylamino)-5-phenyl-1,3-
dihydrobenzo[e][1,4]diazepin-2-one 676128-35-1P,
3-(3-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one
676128-36-2P, 5-Phenyl-3-(2-trifluoromethylbenzylamino)-1,3-
dihydrobenzo[e][1,4]diazepin-2-one 676128-37-3P,
5-Phenyl-3-(3-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-
2-one 676128-38-4P, 5-Phenyl-3-(4-trifluoromethylbenzylamino)-
1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-39-5P,
3-[(Furan-2-ylmethyl)amino]-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-
one 676128-40-8P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)isobutyramide 676128-41-9P,
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)methanesulfonamide 676128-42-0P, Cyclohexanecarboxylic acid
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
676128-43-1P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)-2-methoxybenzamide 676128-44-2P,
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-
methoxybenzamide 676128-45-3P,
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-
nitrobenzamide 676128-46-4P,
2-(2-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)acetamide 676128-47-5P,
2-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)acetamide 676128-48-6P,
2-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)acetamide 676128-49-7P,
2-(4-Nitrophenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)acetamide 676128-50-0P,
2-(3-Nitrophenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)acetamide 676128-51-1P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(2-
trifluoromethylphenyl)acetamide 676128-52-2P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3-
trifluoromethylphenyl)acetamide 676128-53-3P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(4-
trifluoromethylphenyl)acetamide 676128-54-4P,
1-(2-Methoxyphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)urea 676128-55-5P, 1-(2-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-
dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-57-7P,
1-(2-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)urea 676128-59-9P, 1-(4-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-

dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-61-3P,
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(p-
tolyl)urea 676128-62-4E,
1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)urea 676128-63-5P 676128-64-6P,
1-(4-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)urea 676128-65-7P, 4-Methylsulfonyl-2-methoxy-N-(2-oxo-5-
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide
676128-67-9P, 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)benzamide 676128-69-1P,
6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
676128-72-6P, 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)benzamide 676128-74-8P,
2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzamide 676128-76-0P, 1H-Indole-7-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
676128-78-2P, 3-Methoxynaphthalene-2-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
676128-80-6P, N-[7-Chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-81-7P,
1-(2-Fluorobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)urea 676128-82-8E,
1-(4-Methoxybenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)urea 676128-83-9P, 1-(3-Methylbenzyl)-3-(2-oxo-5-phenyl-2,3-
dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-84-0P,
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-
trifluoromethylphenyl)urea 676128-85-1P,
4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)benzamide 676128-86-2P,
4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzamide 676128-87-3P,
3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzamide 676128-88-4P,
5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)benzamide 676128-89-5P,
5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)benzamide 676128-90-6P,
5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzamide 676128-91-9P,
3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzamide 676128-92-0P,
3-(2-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)propionamide 676128-93-1P,
3-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)propionamide 676128-94-2P,
3-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
3-yl)propionamide 676128-95-3P,
N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-
methoxybenzamide 676128-99-7P,
4-Methoxy-N-[2-oxo-5-(4-trifluoromethylphenyl)-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl]benzamide 676129-00-3P,
2-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl]benzamide 676129-01-4P,
4-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl]benzamide 676129-02-5P,
2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzamide 676129-03-6P,
2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)benzamide 676129-04-7P,

2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-05-6P,
 2-Methoxy-N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-07-6P,
 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-08-1P,
 2-Chloro-4-methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-09-2P,
 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-10-5P,
 1-(3,5-Dimethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-11-6P,
 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethoxyphenyl)urea 676129-12-7P,
 1-(4-Bromo-2-trifluoromethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-13-8P,
 1-(4-Bromobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-14-9P, 1-(2,3-Dichlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-15-0P,
 1-(2,6-Dimethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-16-1P,
 1-(2-Chloro-6-methylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-17-2P,
 1-(4-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-18-3P, 1-(2-Methylsulfonylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-19-4P,
 1-(2,6-Dichlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-20-7P,
 5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-21-8P,
 2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-22-9P,
 1-(2,6-Difluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-23-0P,
 1-(3-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-25-2P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-trifluoromethylphenyl)urea 676129-27-4P, 1-(3-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-29-6P,
 2-Methoxy-4-methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-30-9P,
 4-Methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-31-6P,
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamide methyl ester 676129-32-1P,
 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-33-2P,
 2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-34-3P,
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-propoxybenzamide 676129-35-4P,
 2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-36-5P,
 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamide methyl ester 676129-37-6P,
 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-38-7P,
 2-Methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-39-8P,
 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-

sulfamoylbenzamide 676129-49-1P,
2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-41-2E,
3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-42-3P,
3-(2-Fluorophenyl)-1-methyl-1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-43-4P,
2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-44-5E,
1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-45-6P, 1-Cyclohexyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-46-7E,
1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-47-8P, 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-48-9P,
4,5-Dimethylfuran-2-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-49-0P, Piperidine-1-carboxylic acid
N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-57-0P, 5-Methylfuran-2-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-63-8P, Cyclohexanecarboxylic acid
N-(8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-64-9P, Thiophene-2-carboxylic acid
N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-65-0P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(thiophen-2-yl)urea 676129-66-1P,
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(thiophen-3-yl)urea 676129-67-2P, Pyridine-2-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-68-3P, 1H-Pyrazole-4-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-69-4P, 6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 676129-70-7P,
2-Ethoxynaphthalene-1-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-71-8P, 9-Oxo-9H-fluorene-1-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-72-9P, 2-Oxo-2,3-dihydrobenzimidazole-1-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-75-2P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid methyl ester 676129-76-3P,
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid ethyl ester 676129-77-4P,
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid isobutyl ester 676129-78-5P,
2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(thiophen-2-yl)acetamide 676129-79-6P,
6-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 865470-96-8P,
6-(4-Methylpiperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 865470-97-9P,
3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 965471-60-9P, 2-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 865471-65-4P,
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-phenoxyphenyl)urea 865475-39-4P,
2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethylbenzamide 865475-46-7P,

4,5-Dibromofuran-2-carboxylic acid

N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
865475-41-8P, Benzofuran-2-carboxylic acid

N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
865475-43-0P, 2-(1,1-Dioxothiomorpholin-4-yl)-N-(2-oxo-5-phenyl-

2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 865475-45-2P

, 2-Chloro-4-(morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-47-4P,
2-(1,1-Dioxothiomorpholin-4-yl)-4-fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-48-5P,
5-Chloro-2-(1,1-dioxothiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-49-6P,
2-(1,1-Dioxothiomorpholin-4-yl)-5-fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-50-9P,
5-(4-Methylpiperazin-1-ylmethyl)furan-2-carboxylic acid

N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
865475-51-0P, 5-[(Pyrrolidin-1-yl)methyl]furan-2-carboxylic acid

N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
865475-52-1P, 5-[(Piperidin-1-yl)methyl]furan-2-carboxylic acid

N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
865475-53-2P, 5-[(Dimethylamino)methyl]furan-2-carboxylic acid

N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
865475-54-3P, 4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)-2-(piperidin-1-yl)benzamide
865475-57-6P, 4-Fluoro-2-(morpholino)-4-yl-N-(2-oxo-5-phenyl-2,3-

dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 865475-59-8P,
4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-

(pyrrolidin-1-yl)benzamide 865475-61-2P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(pyrrolidin-

1-yl)-4-trifluoromethylbenzamide 865475-62-3P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(piperidin-

1-yl)-4-trifluoromethylbenzamide 865475-63-4P,
2-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-

3-yl)-4-trifluoromethylbenzamide 865475-64-5P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(pyrrolidin-

1-yl)-5-trifluoromethylbenzamide 865475-65-6P,
2-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-

3-yl)-5-trifluoromethylbenzamide 865475-66-7P,
2-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-

3-yl)nicotinamide 865475-67-8P,
2-(1,1-Dioxothiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)nicotinamide 865475-68-9P,
2-(1,1-Dioxothiomorpholin-4-yl)-3-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-69-0P,
2-(1,1-Dioxothiomorpholin-4-yl)-4-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-70-3P,
2-(1,1-Dioxothiomorpholin-4-yl)-6-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-71-4P,
2-Chloro-6-(1,1-dioxothiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)benzamide 865475-72-5P,
3-Cyclopropyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1-carboxylic acid

N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
865475-73-6P, 3-[(4-Methylpiperazin-1-yl)sulfonyl]-N-(2-oxo-5-

phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide
865475-74-7P, 4-(4-Methylpiperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-

dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 865475-75-8P,
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-[(piperidin-

1-yl)sulfonyl]benzamide 865475-76-9P,
3-[(Morpholin-4-yl)sulfonyl]-N-(2-oxo-5-phenyl-2,3-dihydro-1H-


benzo[e][1,4]diazepin-3-yl)benzamide 865475-77-0P,

5-[(Morpholin-4-yl)methyl]furan-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-78-1P, 5-Hydroxymethylfuran-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-79-2P, 5-(1,1-Dioxothiomorpholin-4-ylmethyl)furan-2-
 carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)amide 865475-80-5P, 2-Chloro-4-(1,1-dioxothiomorpholin-4-yl)-
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide
 865475-81-6P, 2-Chloro-5-(1,1-dioxothiomorpholin-4-yl)-N-(2-oxo-5-
 phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide
 865475-82-7P, 5-[[2-(
 Methylsulfonylmethyl) (methyl)amino]methyl]furan-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-83-8P, 2-(Pyridin-3-yl)thiazole-4-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-84-9P, 2-(Pyridin-4-yl)thiazole-4-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-85-0P, 4-Methyl-2-(pyrazin-2-yl)thiazole-5-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-86-1P, 2-[(Morpholin-4-yl)methyl]furan-3-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-87-2P, 3-[(Morpholin-4-yl)methyl]-N-(2-oxo-5-phenyl-2,3-
 dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 865475-88-3P,
 5-[(Morpholin-4-yl)methyl]isoxazole-3-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-89-4P, 3-[(Morpholin-4-yl)methyl]furan-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-90-7P, 5-(Pyridin-2-yl)thiophene-2-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 865475-92-9P, 2-Methyl-4-[(morpholin-4-yl)sulfonyl]furan-3-
 carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)amide 865475-94-1P, 3-[(Morpholin-4-yl)methyl]thiophene-2-
 carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)amide 865475-95-2P, 5-[(Morpholin-4-yl)methyl]thiophene-2-
 carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
 yl)amide 865475-96-3P, 5-Phenyloxazole-4-carboxylic acid
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)

(asym. synthesis of 3-aminobenzodiazepines via oximation of
 benzodiazepines with isoamyl nitrite followed by Ru/C-catalyzed
 hydrogenation and crystallization induced dynamic resolution)


RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-
 yl)- (CA INDEX NAME)




RN 70890-53-8 CAPLUS

CN Acetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA
 INDEX NAME)




RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 108895-98-3 CAPLUS

CN Carbamic acid, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (CA INDEX NAME)




RN 116842-74-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 119506-69-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methoxyphenyl)- (CA INDEX NAME)




RN 150964-48-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 168162-29-6 CAPLUS

CN Carbamic acid, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 206115-23-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 368870-46-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 368870-47-7 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 368870-49-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 368870-50-2 CAPLUS

CN 2-Furancarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676127-95-0 CAPLUS

CN Urea, N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N,N-diethyl- (CA INDEX NAME)




RN 676127-96-1 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676127-97-2 CAPLUS

CN Butanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676127-98-3 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (CA INDEX NAME)




RN 676127-99-4 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,2-dimethyl- (CA INDEX NAME)




RN 676128-00-0 CAPLUS

CN Cyclopentanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-01-1 CAPLUS

CN Cyclohexanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-02-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (CA INDEX NAME)




RN 676128-03-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (CA INDEX NAME)




RN 676128-04-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676128-05-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 676128-06-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-07-7 CAPLUS

CN 4-Morpholinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-08-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (CA INDEX NAME)




RN 676128-09-9 CAPLUS

CN Benamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (CA INDEX NAME)




RN 676128-10-2 CAPLUS

CN 1-Piperazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl- (CA INDEX NAME)




RN 676128-11-3 CAPLUS

CN Benamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)




RN 676128-12-4 CAPLUS

CN Benamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-13-5 CAPLUS

CN Benamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (CA INDEX NAME)




RN 676128-14-6 CAPLUS

CN Benamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (CA INDEX NAME)



RN 676128-15-7 CAPLUS


CN Benamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-nitro- (CA INDEX NAME)



RN 676128-16-8 CAPLUS


CN Benamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-17-9 CAPLUS

CN Benzo[b]thiophene-3-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-18-0 CAPLUS

CN 5-Benzofurancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro- (CA INDEX NAME)



RN 676128-19-1 CAPLUS


CN 5-Isioxazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-20-4 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-

benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-21-5 CAPLUS

CN 3-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-22-6 CAPLUS

CN 4-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-23-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-24-8 CAPLUS

CN Methanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-25-9 CAPLUS

CN 1-Propanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-26-0 CAPLUS

CN 1-Butanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-27-1 CAPLUS

CN Benzenesulfonamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-28-2 CAPLUS

CN Benzenesulfonamide, 3-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-29-3 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-30-6 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (CA INDEX NAME)




RN 676128-31-7 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[(2-nitrophenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)




RN 676128-32-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[(3-nitrophenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)




RN 676128-33-9 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[(4-nitrophenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)




RN 676128-34-0 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[(2-methoxyphenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)




RN 676128-35-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[(3-methoxyphenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)




RN 676128-36-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 676128-37-3 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 676128-38-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 676128-39-5 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-[(2-furanylmethyl)amino]-1,3-dihydro-5-phenyl- (CA INDEX NAME)




RN 676128-40-8 CAPLUS

CN Propanamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (CA INDEX NAME)




RN 676128-41-9 CAPLUS

CN Methanesulfonamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-42-0 CAPLUS

CN Cyclohexanecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-43-1 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676128-44-2 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (CA INDEX NAME)




RN 676128-45-3 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (CA INDEX NAME)




RN 676128-46-4 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676128-47-5 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
3-methoxy- (CA INDEX NAME)




RN 676128-48-6 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
4-methoxy- (CA INDEX NAME)




RN 676128-49-7 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
4-nitro- (CA INDEX NAME)




RN 676128-50-0 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
3-nitro- (CA INDEX NAME)




RN 676128-51-1 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
2-(trifluoromethyl)- (CA INDEX NAME)




RN 676128-52-2 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
3-(trifluoromethyl)- (CA INDEX NAME)




RN 676128-53-3 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
4-(trifluoromethyl)- (CA INDEX NAME)




RN 676128-54-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-methoxyphenyl)- (CA INDEX NAME)




RN 676128-55-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-nitrophenyl)- (CA INDEX NAME)




RN 676128-57-7 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-59-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-61-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-methylphenyl)- (CA INDEX NAME)



RN 676128-62-4 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)- (CA INDEX NAME)



RN 676128-63-5 CAPLUS


CN Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(2-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-64-6 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-fluorophenyl)- (CA INDEX NAME)




RN 676128-65-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylsulfonyl)- (CA INDEX NAME)




RN 676128-67-9 CAPLUS

CN Benzamide, 5-acetyl-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (CA INDEX NAME)




RN 676128-69-1 CAPLUS

CN 4H-1,3-Benzodioxin-8-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-fluoro- (CA INDEX NAME)




RN 676128-72-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4,5-trifluoro- (CA INDEX NAME)




RN 676128-74-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-hydroxy- (CA INDEX NAME)




RN 676128-76-0 CAPLUS

CN 1H-Indole-7-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-78-2 CAPLUS

CN 2-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (CA INDEX NAME)




RN 676128-80-6 CAPLUS

CN Benzamide, N-[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (CA INDEX NAME)




RN 676128-81-7 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(2-fluorophenyl)methyl]- (CA INDEX NAME)




RN 676128-82-8 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 676128-83-9 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 676128-84-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 676128-85-1 CAPLUS

CN Benzamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676128-86-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy-3-nitro- (CA INDEX NAME)




RN 676128-87-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-2-nitro- (CA INDEX NAME)




RN 676128-88-4 CAPLUS

CN Benzamide, 5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676128-89-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-fluoro-2-methoxy- (CA INDEX NAME)




RN 676128-90-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy-2-nitro- (CA INDEX NAME)




RN 676128-91-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-4-nitro- (CA INDEX NAME)




RN 676128-92-0 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676128-93-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (CA INDEX NAME)




RN 676128-94-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (CA INDEX NAME)




RN 676128-95-3 CAPLUS

CN Benzenepropanamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (CA INDEX NAME)




RN 676128-99-7 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (CA INDEX NAME)




RN 676129-00-3 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (CA INDEX NAME)




RN 676129-01-4 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (CA INDEX NAME)




RN 676129-02-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (CA INDEX NAME)




RN 676129-03-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4-dimethoxy- (CA INDEX NAME)




RN 676129-04-7 CAPLUS

CN Benzamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy- (CA INDEX NAME)




RN 676129-05-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676129-07-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676129-08-1 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (CA INDEX NAME)




RN 676129-09-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(dimethylamino)- (CA INDEX NAME)




RN 676129-10-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3,5-dimethylphenyl)- (CA INDEX NAME)




RN 676129-11-6 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-(trifluoromethoxy)phenyl)- (CA INDEX NAME)




RN 676129-12-7 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-bromo-2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 676129-13-8 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-bromo-2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 676129-14-9 CAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-15-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2,6-dimethylphenyl)- (CA INDEX NAME)




RN 676129-16-1 CAPLUS

CN Urea, N-(2-chloro-6-methylphenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-17-2 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-nitrophenyl)- (CA INDEX NAME)




RN 676129-18-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-(methylthio)phenyl)- (CA INDEX NAME)




RN 676129-19-4 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-20-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1,1-dimethylethyl)-2-methoxy- (CA INDEX NAME)




RN 676129-21-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,5-dimethoxy- (CA INDEX NAME)




RN 676129-22-9 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-23-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-fluorophenyl)- (CA INDEX NAME)




RN 676129-25-2 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 676129-27-4 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-29-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylthio)- (CA INDEX NAME)




RN 676129-30-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (CA INDEX NAME)




RN 676129-31-0 CAPLUS

CN Benzoic acid, 4-[[(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 676129-32-1 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (CA INDEX NAME)




RN 676129-33-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,6-difluoro- (CA INDEX NAME)




RN 676129-34-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-propoxy- (CA INDEX NAME)




RN 676129-35-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-iodo- (CA INDEX NAME)




RN 676129-36-5 CAPLUS

CN Benzoic acid, 4-[[2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-3-methoxy-, methyl ester (CA INDEX NAME)




RN 676129-37-6 CAPLUS

CN Benzamide, 4-amino-5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676129-38-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(methylthio)- (CA INDEX NAME)




RN 676129-39-8 CAPLUS

CN Benamide, 5-(aminosulfonyl)-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)




RN 676129-40-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- α -hydroxy- (CA INDEX NAME)




RN 676129-41-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- β -hydroxy- (CA INDEX NAME)




RN 676129-42-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 676129-43-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-N-methyl-4-nitro- (CA INDEX NAME)




RN 676129-44-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 676129-45-6 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-ethyl- (CA INDEX NAME)




RN 676129-46-7 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-ethyl- (CA INDEX NAME)




RN 676129-47-8 CAPLUS

CN Urea, N-butyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-
(CA INDEX NAME)




RN 676129-48-9 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4,5-dimethyl- (CA INDEX NAME)




RN 676129-49-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-57-0 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methyl- (CA INDEX NAME)




RN 676129-63-8 CAPLUS

CN Cyclohexanecarboxamide, N-(8-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-64-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-65-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-2-thienyl- (CA INDEX NAME)




RN 676129-66-1 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-3-thienyl- (CA INDEX NAME)




RN 676129-67-2 CAPLUS

CN 2-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-68-3 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676129-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(dimethylamino)- (CA INDEX NAME)




RN 676129-70-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (CA INDEX NAME)




RN 676129-71-8 CAPLUS

CN 9H-Fluorene-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-9-oxo- (CA INDEX NAME)




RN 676129-72-9 CAPLUS

CN 1H-Benzimidazole-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro-2-oxo- (CA INDEX NAME)




RN 676129-75-2 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-76-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 676129-77-4 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 676129-78-5 CAPLUS

CN 2-Thiopheneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-α-oxo- (CA INDEX NAME)




RN 676129-79-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)




RN 865470-96-8 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 865470-97-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(1-piperidinyl)- (CA INDEX NAME)




RN 865471-60-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(4-morpholinyl)- (CA INDEX NAME)




RN 865471-65-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 865475-39-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(trifluoromethyl)- (CA INDEX NAME)




RN 865475-40-7 CAPLUS

CN 2-Furancarboxamide, 4,5-dibromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 865475-41-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 865475-43-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 865475-45-2 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 865475-47-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)-4-fluoro- (CA INDEX NAME)




RN 865475-48-5 CAPLUS

CN Benzamide, 5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 865475-49-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)-5-fluoro- (CA INDEX NAME)




RN 865475-50-9 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 865475-51-0 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1-pyrrolidinylmethyl)- (CA INDEX NAME)




RN 865475-52-1 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1-piperidinylmethyl)- (CA INDEX NAME)




RN 865475-53-2 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[(dimethylamino)methyl]- (CA INDEX NAME)




RN 865475-54-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-fluoro-2-(1-piperidinyl)- (CA INDEX NAME)




RN 865475-57-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-fluoro-2-(4-morpholinyl)- (CA INDEX NAME)




RN 865475-59-8 CAPLUS

CN Benzamide, 4-cyano-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 865475-61-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (CA INDEX NAME)




RN 865475-62-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1-piperidinyl)-4-(trifluoromethyl)- (CA INDEX NAME)




RN 865475-63-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(4-morpholinyl)-4-(trifluoromethyl)- (CA INDEX NAME)




RN 865475-64-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1-pyrrolidinyl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 865475-65-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(4-morpholinyl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 865475-66-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(4-morpholinyl)- (CA INDEX NAME)




RN 865475-67-8 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 865475-68-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)-3-methyl- (CA INDEX NAME)




RN 865475-69-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)-4-methyl- (CA INDEX NAME)




RN 865475-70-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(1,1-dioxido-4-thiomorpholinyl)-6-methyl- (CA INDEX NAME)




RN 865475-71-4 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 865475-72-5 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-1-carboxamide, 3-cyclopropyl-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro-2-oxo- (CA INDEX NAME)




RN 865475-73-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-[(4-methyl-1-piperazinyl)sulfonyl]- (CA INDEX NAME)




RN 865475-74-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 865475-75-8 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(1-piperidinylsulfonyl)- (CA INDEX NAME)



RN 865475-76-9 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(4-

morpholinylsulfonyl)- (CA INDEX NAME)




RN 865475-77-0 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 865475-78-1 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(hydroxymethyl)- (CA INDEX NAME)




RN 865475-79-2 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]- (CA INDEX NAME)




RN 865475-80-5 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 865475-81-6 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 865475-82-7 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[methyl[2-(methylsulfonyl)ethyl]amino]methyl)- (CA INDEX NAME)




RN 865475-83-8 CAPLUS

CN 4-Thiazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 865475-84-9 CAPLUS

CN 4-Thiazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)




RN 865475-85-0 CAPLUS

CN 5-Thiazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl-2-(2-pyrazinyl)- (CA INDEX NAME)




RN 865475-86-1 CAPLUS

CN 3-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 865475-87-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 865475-88-3 CAPLUS

CN 3-Isioxazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 865475-89-4 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 865475-90-7 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(2-pyridinyl)- (CA INDEX NAME)




RN 865475-92-9 CAPLUS

CN 3-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl-4-(4-morpholinylsulfonyl)- (CA INDEX NAME)




RN 865475-94-1 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 865475-95-2 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 865475-96-3 CAPLUS

CN 4-Oxazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-phenyl- (CA INDEX NAME)




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2000:69206 CAPLUS [Full-text](#)
 DN 132:237070
 TI Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419
 AU Tabuchi, Seiichiro; Ito, Harunobu; Sogabe, Hajime; Kuno, Masako; Kinoshita, Takayoshi; Katumi, Ikuyo; Yamamoto, Naoko; Mitsui, Hitoshi; Satoh, Yoshinari
 CS Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
 SO Chemical & Pharmaceutical Bulletin (2000), 48(1), 1-15
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 OS CASREACT 132:237070
 GI



AB In our continuing research for dual CCK-A and -B antagonists, according to our hypothesis that dual CCK-A and -B antagonists should be more efficacious than selective CCK-A antagonists for the treatment of pancreatitis, we have prepared various 5-alkyl-9-methyl-1,4-benzodiazepines, e.g. I. From the compds. prepared, I was selected as a candidate for development due to its well-balanced high affinity for both receptors. The R-enantiomer of I, (R)-I (FR 208419), had 27-fold higher affinity for the CCK-A receptor and 8-fold more potent CCK-B receptor binding activity than (S)-I. The biol. activity after p.o. administration of (R)-I, estimated from the ID50 value (0.23 mg/kg p.o.) obtained by preliminary evaluation by gastric emptying effects, is considered to be high enough for further development. This compound is now undergoing further biol. evaluations with a view to clin. development.
 IT 261919-63-5P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of alkylmethylbenzodiazepines as dual CCK-A and CCK-B receptor antagonists)
 RN 261919-63-5 CAPLUS
 CN Urea, N-[(3S)-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 206000-73-7P 206000-80-9P 206001-23-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and structure activity relationships of alkylmethylbenzodiazepines as dual CCK-A and CCK-B receptor antagonists)


RN 206000-71-7 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-5-(hydroxymethyl)-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206000-80-8 CAPLUS

CN Urea, N-[5-[1-(acetyloxy)methyl]-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)



RN 206001-28-7 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




IT 206000-68-2P 206000-72-8P 206000-88-6P
206000-94-4P 206000-99-9P 206001-00-5P
206001-01-6P 206001-08-3P 206001-14-1P
206001-34-5P 206001-39-0P 206001-40-3P
206001-41-4P 206001-42-5P 206001-43-6P
206001-44-7P 206001-45-8P 206001-46-9P
206001-47-0P 206001-57-2P 206001-58-3P
261919-60-2P 261919-61-3P 261919-62-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure activity relationships of alkylmethylbenzodiazepines as dual CCK-A and CCK-B receptor antagonists)


RN 206000-68-2 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-cyclohexyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206000-72-8 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-9-methyl-5-[(methylthio)methyl]-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206000-88-6 CAPLUS

CN Urea, N-[1-(2-cyclohexyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206000-94-4 CAPLUS

CN Urea, N-[1-(2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl)-2,3-dihydro-9-methyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206000-99-9 CAPLUS

CN Urea, N-[2,3-dihydro-5,9-dimethyl-1-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-00-5 CAPLUS

CN Urea, N-[2,3-dihydro-5,9-dimethyl-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-01-6 CAPLUS


CN Urea, N-[1-[2-(hexahydro-1(2H)-azocinyl)-2-oxoethyl]-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-08-3 CAPLUS
 CN Urea, N-[1-[2-(hexahydro-1H-azepin-1-yl)-2-oxoethyl]-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)



RN 206001-14-1 CAPLUS
 CN 1H-1,4-Benzodiazepine-1-acetamide, 2,3-dihydro-5,9-dimethyl-3-[[[(3-methylphenyl)amino]carbonyl]amino]-N,N-bis(2-methylpropyl)-2-oxo- (CA INDEX NAME)




RN 206001-34-5 CAPLUS
 CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-5-(methoxymethyl)-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-39-0 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-[(dimethylamino)methyl]-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-40-3 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-cyclopropyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-41-4 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-9-methyl-5-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-42-5 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-43-6 CAPLUS

CN Urea, N-[1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-44-7 CAPLUS

CN Urea, N-[1-(2-cyclohexyl-2-oxoethyl)-2,3-dihydro-9-methyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-45-8 CAPLUS

CN Urea, N-[1-(2-cycloheptyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-46-9 CAPLUS

CN Urea, N-[1-(2-cyclohexyl-2-oxoethyl)-5-cyclopropyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-47-0 CAPLUS

CN Urea, N-[1-(2-cyclopentyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 206001-57-2 CAPLUS

CN Urea, N-[1-(2-cyclooctyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)



RN 206001-58-3 CAPLUS


CN Urea, N-[1-(2-cyclohexyl-2-oxoethyl)-2,3-dihydro-9-methyl-5-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)



RN 261919-60-2 CAPLUS


CN 1H-1,4-Benzodiazepine-1-acetamide, 2,3-dihydro-5,9-dimethyl-N-(1-methylethyl)-3-[[[(3-

methylphenyl)amino]carbonyl]amino]-2-oxo- (CA INDEX NAME)




RN 261919-61-3 CAPLUS

CN Urea, N-[2,3-dihydro-5,9-dimethyl-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)



RN 261919-62-4 CAPLUS

CN Urea, N-[2,3-dihydro-5,9-dimethyl-1-(3-methyl-2-oxobutyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)



IT 205990-40-4P 205991-23-6P 205991-24-8P
 205991-25-9P 205991-26-0P 205992-02-5P
 205992-15-0P 205992-19-4P 205992-20-7P
 205992-29-6P 205992-81-0P 205992-83-2P
 205992-94-5P 205993-09-5P 205993-10-8P
 205993-11-9P 205993-12-0P 205993-16-4P


205993-40-4P 205994-88-3P 205994-89-4P
 205994-90-7P 205994-91-6P 205994-92-9P
 205995-52-4P 205995-63-7P 205995-64-8P
 205995-65-9P 205995-82-8P 205995-91-4P
 205995-95-5P 205995-96-6P 205995-97-7P
 205995-98-8P 205996-00-5P 205996-01-6P
 205996-02-7P 205996-03-8P 205996-04-9P
 205996-05-0P 205996-10-7P 205996-21-0P
 205996-24-3P 205996-25-4P 205996-36-7P
 205996-41-4P 205996-62-9P 205996-76-5P
 205996-99-2P 205997-04-2P 205997-11-1P
 205997-16-6P 205997-21-3P 205997-26-8P
 205998-68-1P 205998-72-7P 205998-75-0P
 205998-77-2P 205999-92-4P 206000-97-7P
 261919-55-6P 261919-57-7P 261919-58-6P
 261919-59-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and structure activity relationships of alkylmethylbenzodiazepines as dual CCK-A and CCK-B receptor antagonists)


RN 205990-49-4 CAPLUS

CN Carbamic acid, (5-cyclohexyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 205991-22-6 CAPLUS


CN 1H-1,4-Benzodiazepine-1-acetic acid, 5-cyclohexyl-2,3-dihydro-9-methyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 205991-24-8 CAPLUS


CN 1H-1,4-Benzodiazepine-1-acetic acid, 5-cyclohexyl-2,3-dihydro-9-methyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-

(CA INDEX NAME)




RN 205991-25-9 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-cyclohexyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 205991-26-0 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-cyclohexyl-1,3-dihydro-9-methyl- (CA INDEX NAME)



RN 205992-02-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,


2,3-dihydro-5,9-dimethyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 205992-15-0 CAPLUS


CN 1H-1,4-Benzodiazepine-1-acetic acid,

2,3-dihydro-5,9-dimethyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]- (CA INDEX NAME)




RN 205992-19-4 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205992-20-7 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-1,3-dihydro-5,9-dimethyl- (CA INDEX NAME)




RN 205992-29-6 CAPLUS

CN Urea, N-[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-5,9-dimethyl-4-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-
(CA INDEX NAME)




RN 205992-81-0 CAPLUS

CN Carbamic acid, [1-(2-cyclohexyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205992-83-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclohexyl-2-oxoethyl)-1,3-dihydro-5,9-dimethyl- (CA INDEX NAME)




RN 205992-94-5 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(3,3-dimethyl-2-oxobutyl)-1,3-dihydro-5,9-dimethyl- (CA INDEX NAME)




RN 205993-09-5 CAPLUS

CN Carbamic acid, [2,3-dihydro-9-methyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205993-10-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-9-methyl-5-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 205993-11-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
2,3-dihydro-9-methyl-5-(1-methylethyl)-2-oxo-3-
[[(phenylmethoxy) carbonyl] amino]- (CA INDEX NAME)




RN 205993-12-0 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-
9-methyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl
ester (9CI) (CA INDEX NAME)




RN 205993-16-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-
oxoethyl]-1,3-dihydro-9-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 205993-40-4 CAPLUS

CN Carbamic acid, (2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205994-88-3 CAPLUS

CN Carbamic acid, [2,3-dihydro-5-(methoxymethyl)-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205994-89-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-5-(methoxymethyl)-9-methyl-2-oxo-3-[[(phenylmethoxy)carbonylamino]-, ethyl ester (CA INDEX NAME)




RN 205994-90-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
2,3-dihydro-5-(methoxymethyl)-9-methyl-2-oxo-3-
[[(phenylmethoxy) carbonyl] amino]- (CA INDEX NAME)




RN 205994-91-8 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-5-(methoxymethyl)-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 205994-92-9 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-1,3-dihydro-5-(methoxymethyl)-9-methyl- (CA INDEX NAME)



RN 205995-52-4 CAPLUS


CN Carbamic acid, [5-[(dimethylamino)methyl]-2,3-dihydro-9-methyl-2-oxo-1H-

1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205995-63-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
5-[(dimethylamino)methyl]-2,3-dihydro-9-methyl-2-oxo-3-
[[phenylmethoxy]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 205995-64-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
5-[(dimethylamino)methyl]-2,3-dihydro-9-methyl-2-oxo-3-
[[phenylmethoxy]carbonyl]amino]- (CA INDEX NAME)




RN 205995-65-9 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-
[(dimethylamino)methyl]-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-
yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205995-82-0 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-[(dimethylamino)methyl]-1,3-dihydro-9-methyl- (CA INDEX NAME)




RN 205995-94-4 CAPLUS

CN Carbamic acid, (5-cyclopropyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205995-95-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid, 5-cyclopropyl-2,3-dihydro-9-methyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 205995-96-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
5-cyclopropyl-2,3-dihydro-9-methyl-2-oxo-3-
[[(phenylmethoxy) carbonyl] amino]- (CA INDEX NAME)




RN 205995-97-7 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-
cyclopropyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-,
phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205995-98-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-
oxoethyl]-5-cyclopropyl-1,3-dihydro-9-methyl- (CA INDEX NAME)




RN 205996-00-5 CAPLUS

CN Carbamic acid, [2,3-dihydro-9-methyl-5-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205996-01-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-9-methyl-5-(2-methylpropyl)-2-oxo-3-[[[(phenylmethoxy)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 205996-02-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-9-methyl-5-(2-methylpropyl)-2-oxo-3-[[[(phenylmethoxy)carbonyl]amino]- (CA INDEX NAME)




RN 205996-03-8 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-2,3-dihydro-9-methyl-5-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205996-04-9 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-1,3-dihydro-9-methyl-5-(2-methylpropyl)- (CA INDEX NAME)



RN 205996-05-0 CAPLUS


CN Carbamic acid, (5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 205996-10-7 CAPLUS


CN 1H-1,4-Benzodiazepine-1-acetic acid, 5-ethyl-2,3-dihydro-9-methyl-2-oxo-3-[[(phenylmethoxy) carbonyl] amino]-,

ethyl ester (CA INDEX NAME)




RN 205996-21-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
5-ethyl-2,3-dihydro-9-methyl-2-oxo-3-[(phenylmethoxy)carbonylamino]-
(CA INDEX NAME)




RN 205996-24-3 CAPLUS

CN Carbamic acid, [1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester
(9CI) (CA INDEX NAME)




RN 205996-25-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-ethyl-1,3-dihydro-9-methyl- (CA INDEX NAME)




RN 205996-36-7 CAPLUS

CN Carbamic acid, [1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205996-41-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-1,3-dihydro-9-methyl- (CA INDEX NAME)




RN 205996-62-9 CAPLUS

CN Carbamic acid, [1-(2-cyclohexyl-2-oxoethyl)-2,3-dihydro-9-methyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205996-76-5 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclohexyl-2-oxoethyl)-1,3-dihydro-9-methyl-5-(1-methylethyl)- (CA INDEX NAME)



RN 205996-99-2 CAPLUS


CN Carbamic acid, [1-(2-cycloheptyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 205997-04-2 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cycloheptyl-2-oxoethyl)-1,3-

dihydro-5,9-dimethyl- (CA INDEX NAME)




RN 205997-11-1 CAPLUS

CN Carbamic acid, [1-(2-cyclohexyl-2-oxoethyl)-5-cyclopropyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205997-16-6 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclohexyl-2-oxoethyl)-5-cyclopropyl-1,3-dihydro-9-methyl- (CA INDEX NAME)




RN 205997-21-3 CAPLUS

CN Carbamic acid, [1-(2-cyclopentyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205997-26-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclopentyl-2-oxoethyl)-1,3-dihydro-5,9-dimethyl- (CA INDEX NAME)




RN 205998-68-1 CAPLUS

CN Carbamic acid, [1-(2-cyclooctyl-2-oxoethyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 205998-72-7 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclooctyl-2-oxoethyl)-1,3-dihydro-5,9-dimethyl- (CA INDEX NAME)




RN 205998-75-0 CAPLUS

CN Carbamic acid, [1-(2-cyclohexyl-2-oxoethyl)-2,3-dihydro-9-methyl-5-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)




RN 205998-77-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclohexyl-2-oxoethyl)-1,3-dihydro-9-methyl-5-(2-methylpropyl)- (CA INDEX NAME)




RN 205999-92-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
2,3-dihydro-5,9-dimethyl-3-[[[(3-methylphenyl)amino]carbonyl]amino]-2-oxo-
, ethyl ester (CA INDEX NAME)




RN 206000-97-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid,
2,3-dihydro-5,9-dimethyl-3-[[[(3-methylphenyl)amino]carbonyl]amino]-2-oxo-
(CA INDEX NAME)




RN 261919-56-6 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5,9-dimethyl- (CA INDEX
NAME)




RN 261919-57-7 CAPLUS

CN Urea, N-(2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 261919-58-8 CAPLUS

CN Carbamic acid, [2,3-dihydro-5,9-dimethyl-1-[2-(methyl-2-pyridinylamino)-2-oxoethyl]-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 261919-59-9 CAPLUS

CN Carbamic acid, [1-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-5,9-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT 206001-63-0P 206001-64-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(stereoselective preparation and structure activity relationships of alkylmethylbenzodiazepines as dual CCK-A and CCK-B receptor antagonists)

RN 206001-63-0 CAPLUS

CN Urea, N-[(3S)-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 206001-64-1 CAPLUS

CN Urea, N-[(3R)-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 205998-79-4P 205998-80-7P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation and structure activity relationships of alkylmethylbenzodiazepines as dual CCK-A and CCK-B receptor antagonists)

RN 205998-79-4 CAPLUS

CN Benzenepropanamide, α -amino-N-[(3R)-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 205998-80-7 CAPLUS

CN Benzenepropanamide, α -amino-N-[(3S)-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 205998-78-3P 205998-81-0P 205998-89-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation and structure activity relationships of alkylmethylbenzodiazepines as dual CCK-A and CCK-B receptor antagonists)

RN 205998-78-3 CAPLUS

CN Carbamic acid, [(1S)-2-[[1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-

, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205998-81-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-1,3-dihydro-9-methyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 205998-89-6 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-1,3-dihydro-9-methyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1999:118450 CAPLUS Full-text

DN 130:237541

TI Crystallization-induced asymmetric transformation:
stereospecific synthesis of L-768,673

AU Shi, Yao-Jun; Wells, Kenneth M.; Pye, Philip J.; Choi, Woo-Baeg;
Churchill, Hywyn R. O.; Lynch, Joseph E.; Maliakal, Ashok; Sager, Jess W.;
Rossen, Kai; Volante, R. P.; Reider, Paul J.

CS Department of Process Research, Merck Research Laboratories, Rahway, NJ,
07065, USA

SO Tetrahedron (1999), 55(4), 909-918

CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 130:237541

AB A highly convergent, asym. synthesis of L-768,673, an Iks Class III
antiarrhythmic drug candidate, is described. Synthesis of the racemic 1-
trifluoroethyl-3-amino-5-Ph benzodiazepinone [(±)-amine] was achieved by Ru-
catalyzed hydrogenation of the corresponding oxime that was derived from com.
available 1-trifluoroethyl-5-phenylbenzodiazepine in 76% overall yield. An
efficient one-pot resolution-racemization of (±)-amine provided the desired
(+)-amine as its mandelate salt in 92% yield and 99.4% ee. Regioselective
ortho-lithiation of 1,3-bis(trifluoromethyl)benzene with n-BuLi in the
presence of a catalytic amount of 2,2',6,6'-tetramethylpiperidine afforded its
aryllithium. Subsequent transmetalation and alkylation with allyl bromide
produced the corresponding olefin. Ru-catalyzed oxidative cleavage of the
terminated double bond of the olefin provided the desired 2,4-
bis(trifluoromethyl)phenylacetic acid in 35% overall yield. A modified
Schotten-Baumann procedure was developed for coupling of (+)-amine and the
acid to produce L-768,673 in 92% yield without racemization.


IT 177954-81-3P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic
preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereospecific synthesis of L-768,673)

RN 177954-81-3 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl-1-(2,2,2-
trifluoroethyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 177954-78-8P 220892-18-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(stereospecific synthesis of L-768,673)

RN 177954-78-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl-1-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)



RN 220892-18-2 CAPLUS


CN Benzeneacetic acid, α -hydroxy-, (α R)-, compd. with
(3R)-3-amino-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 177954-81-3

CMF C17 H14 F3 N3 O

Absolute stereochemistry. Rotation (+).



CM 2

CRN 611-71-2

CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).




IT 177954-68-6P, L768673

RL: SPN (Synthetic preparation); PREP (Preparation)
(stereospecific synthesis of L-768,673)

RN 177954-68-6 CAPLUS


CN Benzeneacetamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-2,4-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1996:95894 CAPLUS Full-text
 DN 124:261001
 OREF 124:48355a,48358a
 TI A facile large scale synthesis of optically active
 3-amino-5-(2-pyridyl)-1,4-benzodiazepin-2-one derivatives
 AU Semple, Graeme; Ryder, Hamish; Ohta, Mitsuaki; Satoh, Masato
 CS Ferring Research Inst., Chilworth Research Centre, Southampton, SO16 7NP,
 UK
 SO Synthetic Communications (1996), 26(4), 721-7
 CODEN: SYNCAV; ISSN: 0039-7911
 PB Dekker
 DT Journal
 LA English
 OS CASREACT 124:261001
 GI




I

AB A facile method for the synthesis of 3-amino-5-(2-pyridyl)-1,4-benzodiazepin-
 2-one I mediated by benzotriazole is described. The synthesis and optical
 resolution of the product by fractional crystallization proceeds in high
 yield, under mild conditions and without recourse to toxic reagents or
 chromatog. sepsis, and hence is amenable to the large scale preparation of
 these important precursors to potent CCK receptor ligands.
 IT 168162-20-7P 168162-21-8P 168162-22-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aminopyridylbenzodiazepinone)
 RN 168162-20-7 CAPLUS
 CN Carbamic acid, [2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-
 yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 168162-21-8 CAPLUS
 CN Carbamic acid, [1-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-
 pyridinyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 168162-22-9 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-(3,3-dimethyl-2-oxobutyl)-1,3-dihydro-5-(2-pyridinyl)- (CA INDEX NAME)



IT 168162-36-5P 168393-74-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aminopyridylbenzodiazepinone)

RN 168162-36-5 CAPLUS


CN Benzeneacetic acid, α -hydroxy-, (α R)-, compd. with
(3R)-3-amino-1-(3,3-dimethyl-2-oxobutyl)-1,3-dihydro-5-(2-pyridinyl)-2H-1,4-benzodiazepin-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 164343-31-1

CMF C20 H22 N4 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 611-71-2

CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).



RN 168393-74-6 CAPLUS


CN Benzeneacetic acid, α -hydroxy-, (S)-, compd. with
(S)-3-amino-1-(3,3-dimethyl-2-oxobutyl)-1,3-dihydro-5-(2-pyridinyl)-2H-1,4-
benzodiazepin-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 168393-73-5

CMF C20 H22 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2


CRN 17199-29-0

CMF C8 H8 O3


Absolute stereochemistry. Rotation (+).



L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1995:700793 CAPLUS [Full-text](#)
 DN 123:314500
 OREF 123:56399a,56402a
 TI Stereochemistry of the benzodiazepine based Ras
 farnesyltransferase inhibitors
 AU Rawson, Thomas E.; Somers, Todd C.; Marsters, James C., Jr.; Wan, Dairian
 T.; Reynolds, Mark E.; Burdick, Daniel J.
 CS Bioorganic Chemistry, Genetech, Inc., South San Francisco, CA, 94080, USA
 SO Bioorganic & Medicinal Chemistry Letters (1995), 5(13), 1335-8
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 GI




I



II


- AB Chiral benzodiazepine I is the preferred dipeptide turn mimic enantiomer employed in a series of Ras farnesyltransferase inhibitors. It was resolved as the camphorsulfonic acid salt of its Me ester via a directed crystallization process. Crystallog. anal. of a derivative established R stereochem. at C-3. The stereochem. of the addnl. two chiral centers in derived inhibitor II is addressed.
 IT 149882-95-1P 170210-76-1P 170210-77-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (stereochem. of benzodiazepine based Ras farnesyltransferase inhibitors)
 RN 149882-95-1 CAPLUS
 CN L-Methionine, N-[[[(3S)-3-[[[(2R)-2-amino-3-mercapto-1-oxopropyl]methylamino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 170210-76-1 CAPLUS
 CN L-Methionine, N-[[[(3S)-3-[[[(2-amino-3-mercapto-1-oxopropyl)methylamino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170210-77-2 CAPLUS

CN D-Methionine, N-[[3-[(2-amino-3-mercapto-1-oxopropyl)methylamino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]-, [S-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 170029-19-3P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (stereochem. of benzodiazepine based Ras farnesyltransferase inhibitors)

RN 170029-19-3 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-3-[methyl(1-oxo-2-phenylpropyl)amino]-2-oxo-5-phenyl-, methyl ester, [S-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 170029-17-1

RL: RCT (Reactant); RACT (Reactant or reagent) (stereochem. of benzodiazepine based Ras farnesyltransferase inhibitors)


RN 170029-17-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-3-(methylamino)-2-oxo-5-phenyl-, methyl ester (CA INDEX NAME)



IT 170029-16-0P 170029-16-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (stereochem. of benzodiazepine based Ras farnesyltransferase
 inhibitors)
 RN 170029-16-0 CAPLUS
 CN 1H-1,4-Benzodiazepine-1-acetic acid,
 2,3-dihydro-3-(methylamino)-2-oxo-5-phenyl-, methyl ester, (R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 170029-18-2 CAPLUS
 CN 1H-1,4-Benzodiazepine-1-acetic acid,
 2,3-dihydro-3-(methylamino)-2-oxo-5-phenyl-, methyl ester, (R)-,
 mono[(1R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate]
 (9CI) (CA INDEX NAME)

CM 1

CRN 170029-16-0
 CME C19 H19 N3 O3


Absolute stereochemistry. Rotation (+).




CM 2

CRN 35963-20-3
CMF C10 H16 O4 S


Absolute stereochemistry. Rotation (-).



L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1987:156438 CAPLUS [Full-text](#)
 DN 106:156438
 OREF 106:25465a,25468a
 TI Crystallization-induced asymmetric transformation:
 stereospecific synthesis of a potent peripheral CCK antagonist
 AU Reider, Paul J.; Davis, Paul; Hughes, David L.; Grabowski, Edward J. J.
 CS Merck, Sharp and Dohme Res. Lab., Rahway, NJ, 07065, USA
 SO Journal of Organic Chemistry (1987), 52(5), 955-7
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 GI




I




II

AB Racemic benzodiazepinone (RS)-I was converted totally into (S)-I in 91% yield
 via a catalytic, one-pot resolution- racemization sequence. A
 crystallization-induced asym. transformation was achieved using (1S)-(+)-10-
 camphorsulfonic acid in the presence of a catalytic amount of an aromatic
 aldehyde. (S)-I was converted to L-364, 718 (II), a potent CCK antagonist.
 IT 103421-61-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (crystallization-induced asym. transformation of, into S-enantiomer
 via resolution-racemization sequence)
 RN 103421-61-0 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-1-methyl-5-phenyl- (CA
 INDEX NAME)



IT 103343-66-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and conversion of, to L-364, 718)
 RN 103343-66-4 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-1-methyl-5-phenyl-, (3S)-
 (CA INDEX NAME)

Absolute stereochemistry.




IT 107438-84-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 107438-84-6 CAPLUS
 CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
 (1S,4R)-, compd. with (3S)-3-amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-
 benzodiazepin-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 103343-66-4
 CMF C16 H15 N3 O


Absolute stereochemistry.



CM 2

CRN 3144-16-9
 CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



IT 103420-77-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(stereospecific synthesis of, via crystallization-induced
 asym. transformation of racemic aminobenzodiazepinone derivative
 into S-enantiomer)

RN 103420-77-5 CAPLUS

CN 1H-indole-2-carboxamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-
 1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1966:84634 CAPLUS Full-text

DN 64:84634

OREF 64:15902g-h,15903a-h,15904a

TI Ketimines

PA Etablissements Clin-Byla

SO 47 pp.

DT Patent

LA Unavailable

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	NL 6507637	A	19651216	NL 1965-7637	19650615	
	NL 155545	B	19780116			
	IL 23712	A	19690730	IL 1965-23712	19650611	
	IL 32140	A	19690730	IL 1965-32140	19650611	
	SE 336341	B	19710705	SE 1965-7800	19650614	
	DE 1795445	A	19730111	DE 1967-1795445	19650614	
	FI 47986	B	19740131	FI 1965-1408	19650614	
	DE 1795832	A	19760422	DE 1967-1795832	19650614	
	DE 1795832	B2	19800717			
	DE 1795832	C3	19810702			
	SE 386891	B	19760823	SE 1965-386891	19650614	
	DE 1518764	B2	19790621	DE 1965-E29512	19650614	
	CH 479552	A	19691015	CH 1965-479552	19650615	
	CH 485741	A	19700215	CH 1965-485741	19650615	
	AT 284084	B	19700825	AT 1967-8973	19650615	
	NO 120115	B	19700831	NO 1965-158505	19650615	
	BR 6570433	D0	19730814	BR 1965-170433	19650615	
	DK 138493	B	19780918	DK 1965-3001	19650615	
	DK 138493	C	19790226			
	DK 135591	B	19770523	DK 1967-4862	19670929	
	NO 134906	B	19760927	NO 1968-219	19680118	
	US 3516988	A	19700623	US 1968-706713	19680219	
	FI 51586	B	19761101	FI 1969-2643	19690916	
	DK 125856	B	19730514	DK 1970-298	19700122	
	DK 129126	B	19740826	DK 1971-2234	19710510	
	US 28315	E	19750121	US 1972-232985	19720308	
	DK 135590	B	19770523	DK 1972-4563	19720915	
	CA 958707	B	19741203	CA 1972-151906	19720918	
	CA 958708	B	19741203	CA 1972-151907	19720918	
	US 3966793	A	19760629	US 1973-401029	19730926	
	NO 136670	B	19770711	NO 1974-3136	19740902	
	PRAI	FR 1964-978360	A	19640615		
		FR 1965-12886	A	19650412		
		FI 1965-1408	A	19650614		
		US 1965-463613	A	19650614		
DK 1965-3001		A	19650615			
NO 1965-158505		A	19650615			
US 1968-706713		A	19680219			
US 1968-739990		A2	19680219			
US 1968-728468	A	19680515				
GI	For diagram(s), see printed CA Issue.					
AB	A series of open-chain and cyclic ketimines of the general formulas I and II, resp., was prepared. In formula I and II, R1 = H, Cl, Me, NO2, or NH2, R2 = an aryl or cycloalkyl group, R3 = H or Me, and R4 = H, CO2Et, CO2Me, CONH2, CONHMe, CONMe2, or CONHCH2CH2NMe2. PhMgBr from 848 g. PhBr and 109 g. Mg in 3600 cc. dry Et2O treated during about 3.5 hrs. dropwise with 228.7 g. 5,2-Cl(H2N)C6H3CN in 1800 cc. dry Et2O and refluxed 15 hrs. yielded 309 g. 5,2-Cl(H2N)C6H3C(NH)Ph (III), m. 74° (petroleum ether). Similarly prepared were					

the following compds. (m. p. and % yield given): 5,2-Cl(MeNH)C6H3C(:NH)Ph (IV), 97°, 61; o-H2NC6 H4C(:NH)Ph (V), 48° (iso-Pr2O), 80; cyclohexyl 2-amino-5-chlorophenyl ketimine (VI), 65 and 95°, 81; 5,2-Cl(H2N)C6H3C(:NH)Bu, 27-8° (decomposition), 94. III (27.6 g.) and 20.7 g. H2NCH2CO2Et.HCl (VII.HCl) in 150 cc. MeOH stirred 2.5 hrs. at room temperature yielded 32.4 g. I (R1 = Cl, R2 = Ph, R3 = R4 = H, R5 = Et), m. 130-5°, which was separated by fractional recrystn. from Me2CO into 2 stereoisomers, m. 148-50° and 142-4°, resp. IV gave similarly 82% I (R1 = Cl, R2 = Ph, R3 = Me, R4 = H, R5 = Et) (VIII), m. 70-2°, which was separated by fractional recrystn. from hexane into the 2 stereoisomeric forms, m. 110° and 85°, resp. EtNHCH(CO2Et)2.HCl (10.6 g.) in 30 cc. refluxing absolute EtOH treated dropwise with 9.2 g. III in 16 cc. absolute EtOH and refluxed 0.5 hr. yielded 7.8 g. I (R1 = Cl, R2 = Ph, R3 = H, R4 = CO2Et, R5 = Et), m. 106° (iso-Pr2O). Similarly prepared were the following I (R1, R2, R3, R4, R5, m.p., and % yield given): Cl, Ph, H, CO2Et, Et, 106°, 50; Cl, Ph, Me, CO2Et, Et, 88° (iso-Pr2O), 25; H, Ph, H, H, Et, 106° (iso-Pr2O), 58; H, Ph, H, CO2Et, Et, 100° (iso-Pr2O), 31; Me, Ph, H, H, Et, 131° (iso-Pr2O), 35; Cl, Bu, H, H, Et, 96-7° (iso-Pr2O), 55. The crude product from 27.6 g. III and 20.7 g. VII.HCl refluxed 0.5 hr. with 150 cc. AcOH yielded 25.7 g. II (R1 = Cl, R2 = Ph, R3 = R4 = H) (IX), m. 214-16°. 5,2-Cl(H2N)C6H3CPh:NCH(CO2-K)2 (IXa) (0.409 g.) in 4 cc. H2O adjusted with AcOH to pH 4 and heated 15 min. on the water bath also gave 0.216 g. IX. VIII (6 g.) in 25 cc. AcOH refluxed 15 min. gave 4.4 g. II (R1 = Cl, R2 = Ph, R3 = Me, R4 = H) (X), m. 132° (iso-Pr2O). III (6.9 g.) and 5.1 g. DL-alanine.HCl in 40 cc. absolute EtOH refluxed 5 min. in 40 cc. AcOH yielded 5.15 g. II (R1 = Cl, R2 = Ph, R3 = H, R4 = Me), m. 224° (iso-Pr2O). Similarly prepared were the following II (R1 = Cl, R2 = Ph, R3 = H) (R4, m.p., and % yield given): iso-Bu, 213° (AcOEt), 48; MeSCH2CH2, 184°, 50; EtO2C (XI), 244° (AcOEt), 74. III (9.2 g.), 10.6 g. EtNHCH (CO2Et)2.HCl, and 5 g. Et3N in 45 cc. absolute EtOH refluxed 1 hr., and the crude product refluxed 15 min. in 45 cc. AcOH yielded 6.4 g. XI, m. 244°. MeNHCH(CO2Et)2.HCl (9.2 g.) in 30 cc. MeOH treated dropwise during 1.5 hrs. with 9.2 g. III in 20 cc. MeOH and refluxed 0.5 hr., and the product refluxed 15 min. with 25 cc. AcOH yielded 6.2 g. II (R1 = Cl, R2 = Ph, R3 = H, R4 = CO2Me) (XII), m. 226° (MeOH). EtNHCH(CO2Et)2.HCl with IV gave similarly 45% II (R1 = Cl, R2 = Ph, R3 = H, R4 = CO2Et) (XIII), m. 180° (EtOH). XII (10 g.) and 200 cc. 13.6% NH3-MeOH kept at room temperature overnight yielded 7 g. II (R1 = Cl, R2 = Ph, R3 = H, R4 = CONH2) (XIV), m. 255-6° (MeOH). Similarly were prepared from the appropriate amines the following II (R1 = Cl, R2 = Ph, R3 = H) (same data given); CONHMe, 294° (EtOH), 90; CONMe2, 297°, --; Et2NCH2CH2NHCO, 220° (AcOEt), 90. In the same manner were prepared the following compds. II (R1, R2, R3, R4, m. p., and % yield given): H, Ph, H, CO2Et (XV), 226° (AcOEt), 70; Me, Ph, H, H, 208° (AcOEt), Me, Ph, H, CO2Et, 260°, 25. Powdered XV (12.3 g.) added slowly with stirring below 25° to 50 cc. concentrated H2SO4, treated slowly below 25° with 4.8 g. powdered KNO3, and stirred 2.5 hrs. at room temperature yielded 7.7 g. light yellow II (R1 = NO2, R2 = Ph, R3 = H, R4 = CO2Et) (XVI), m. 271° (AcOEt). XVI (4.48 g.) in 80 cc. HCONMe2 and 120 cc. EtOH hydrogenated under ambient conditions over Raney Ni during 3 hrs. yielded 3.9 g. II (R1 = NH2, R2 = Ph, R3 = H, R4 = CO2Et), m. 305° (decomposition). VI with VII.HCl (equimolar amts.) yielded 71% II (R1 = Cl, R2 = cyclohexyl, R3 = R4 = H) (XVII), m. 210° (ProH). EtNHCH(CO2Et)2 with VI gave similarly 40% II (R1 = Cl, R2 = cyclohexyl, R3 = H, R4 = CO2Et), m. 208° (AcOEt). XII (82 g.) treated at 70° with 50 g. KOH in 1350 cc. 96% EtOH and centrifuged yielded quant. IX; the strongly alkaline aqueous solution of IX acidified with AcOH and heated on a water bath gave IX. XI (2 g.) refluxed with 0.84 g. KOH in 1 cc. H2O and 25 cc. MeOH gave 1.25 g. IX. Similarly prepared were the following ArPh:CNCCH(CO2K)2 (XVIII) (Ar, % yield, given): 5,2-Cl(H2N)C6H3 71, o-H2NC6H4 100, 5,2-Me(H2N)C6H3 (XX) 100, 2,5-H2N(O2N)C6H3 (XXI) 100, 2,5-(H2N)2C6H3 100. XIV gave similarly nearly quant. the yellow crystalline 5,2-Cl(H2N)C6H3-CPh:NCH(CONH2)CO2K. IX (1 g.) in 15 cc. H2O treated 10 min. with 0.55 g. CaCl2 in 5 cc. H2O and centrifuged yielded 0.75 g. Ca salt


analog. IX (2.1 g.) and 0.68 g. KH2PO4 in 18 cc. H2O at room temperature gave similarly 1.8 g. K salt analog. XIX gave similarly 74% 3-CO2K analog. Similarly were prepared the 3-CO2K analogs of the corresponding II from XIX, XX, and XXI. EtNHCH(CO2Et)2.HCl (423.5 g.) and 1250 cc. dry C6H6 treated at reflux during 50 min. with 460 g. III in 1250 cc. dry C6H6, refluxed about 2 hrs., treated 2 hrs. with dry HCl, cooled, and centrifuged, and the orange, crystalline product treated with aqueous Na2CO3 and CH2Cl2 gave 441.5 g. XI, m. 243°-4°. EtNHCH(CO2Et)2.HCl (423.5 g.) in 1250 cc. C6H6 and 391 g. V in 1250 cc. C6H6 gave similarly 416 g. II (R1 = R3 = H, R2 = Ph, R4 = CO2Et), m. 224-5°. VI gave similarly 66.5% XVII, m. 208°, XI yielded IX, and XVI gave XXI. XI (6.68 g.) and 4.5 g. KOH in 45 cc. H2O heated with stirring on a water bath, acidified with 6 cc. AcOH, and refluxed briefly gave nearly quant. IX, m. 212°. IX (3 g.), 0.7 g. KOH, and 15 cc. H2O treated during 5 min. with stirring below 25° with 1.8 g. Me2SO4, kept 2 hrs. at room temperature, acidified with AcOH, and refluxed several min. yielded 80% X, m. 132°. The I and II are central nervous system depressants and are useful as psycholeptics, myorelaxants, and tranquilizers. The screening results in mice are tabulated.

IT 5571-37-9F, 1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-nitro-2-oxo-5-phenyl-, ethyl ester 5571-38-0F,
1H-1,4-Benzodiazepine-3-carboxylic acid,
7-amino-2,3-dihydro-2-oxo-5-phenyl-, ethyl ester 5571-40-4P,
1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-5-cyclohexyl-2,3-dihydro-2-oxo-, ethyl ester 5571-44-8F
, 1H-1,4-Benzodiazepine-3-carboxylic acid, 2,3-dihydro-2-oxo-5-phenyl-,
potassium salt 5571-45-9P, 1H-1,4-Benzodiazepine-3-carboxylic
acid, 2,3-dihydro-2-oxo-5-phenyl-, ethyl ester 5571-84-6P,
1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-nitro-2-oxo-5-phenyl-, potassium salt 5571-85-7P,
1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-methyl-2-oxo-5-phenyl-, potassium salt 5571-87-9P,
1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-methyl-2-oxo-5-phenyl-, ethyl ester 5606-55-3P,
1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-2-oxo-5-phenyl-, ethyl ester 5606-56-4P,
1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-2-oxo-5-phenyl-, methyl ester 5606-57-5P,
1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-, ethyl ester
5606-58-6E, 1H-1,4-Benzodiazepine-3-carboxamide,
7-chloro-2,3-dihydro-2-oxo-5-phenyl- 5606-59-7P,
1H-1,4-Benzodiazepine-3-carboxamide,
7-chloro-2,3-dihydro-N-methyl-2-oxo-5-phenyl- 5606-60-0P,
1H-1,4-Benzodiazepine-3-carboxamide,
7-chloro-N-[2-(diethylamino)ethyl]-2,3-dihydro-2-oxo-5-phenyl-
5991-71-9P, 1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt 5991-73-6P,
1H-1,4-Benzodiazepine-3-carboxamide,
7-chloro-2,3-dihydro-N,N-dimethyl-2-oxo-5-phenyl-
RL: PREP (Preparation)

(preparation of)


RN 5571-37-9 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-nitro-2-oxo-5-phenyl-, ethyl ester (CA INDEX NAME)




RN 5571-38-0 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
7-amino-2,3-dihydro-2-oxo-5-phenyl-, ethyl ester (CA INDEX NAME)




RN 5571-40-4 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-5-cyclohexyl-2,3-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)



RN 5571-44-8 CAPLUS


CN 1H-1,4-Benzodiazepine-3-carboxylic acid, 2,3-dihydro-2-oxo-5-phenyl-,
potassium salt (1:1) (CA INDEX NAME)



● K


RN 5571-45-9 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid, 2,3-dihydro-2-oxo-5-phenyl-,
ethyl ester (CA INDEX NAME)



RN 5571-84-6 CAPLUS


CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-nitro-2-oxo-5-phenyl-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 5571-85-7 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-methyl-2-oxo-5-phenyl-, potassium salt (1:1) (CA INDEX
NAME)




RN 5571-87-9 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
2,3-dihydro-7-methyl-2-oxo-5-phenyl-, ethyl ester (CA INDEX NAME)




RN 5606-55-3 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-2-oxo-5-phenyl-, ethyl ester (CA INDEX NAME)




RN 5606-56-4 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-2-oxo-5-phenyl-, methyl ester (CA INDEX NAME)




RN 5606-57-5 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-, ethyl ester (CA INDEX NAME)



RN 5606-58-6 CAPLUS


CN 1H-1,4-Benzodiazepine-3-carboxamide, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-
(CA INDEX NAME)



RN 5606-59-7 CAPLUS


CN 1H-1,4-Benzodiazepine-3-carboxamide,

7-chloro-2,3-dihydro-N-methyl-2-oxo-5-phenyl- (CA INDEX NAME)




RN 5606-60-0 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxamide,
7-chloro-N-[2-(diethylamino)ethyl]-2,3-dihydro-2-oxo-5-phenyl- (CA INDEX NAME)



RN 5991-71-9 CAPLUS


CN 1H-1,4-Benzodiazepine-3-carboxylic acid,
7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 5991-78-6 CAPLUS

CN 1H-1,4-Benzodiazepine-3-carboxamide,
7-chloro-2,3-dihydro-N,N-dimethyl-2-oxo-5-phenyl- (CA INDEX NAME)



=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



G1 Cy,Ak
 G2 N, [1], [2]

Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 21:11:38 ON 23 JUL 2009)

FILE 'REGISTRY' ENTERED AT 21:11:51 ON 23 JUL 2009

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 50 S L2
 L4 8417 S L2 FUL

FILE 'CAPLUS' ENTERED AT 21:12:18 ON 23 JUL 2009

L5 1728 S L4
 L6 99 S L5 AND (OPTIC? OR STEREO? OR RACE?)
 L7 38 S L6 AND (SEPAR? OR RESOL? OR PURIF?)
 L8 8 S L7 AND CRYSTAL?

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	62.80	248.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.56	-6.56

STN INTERNATIONAL LOGOFF AT 21:14:51 ON 23 JUL 2009